1. In Vivo
  2. >>Deal-Making

Podcast: Improving Communication – The Relationship Between Biotech And Pharma

 
• By David Wild

Ali Pashazadeh, CEO, chair and founder of Treehill Partners discusses the need for increased communication between biotech and biopharma. 

In Vivo Podcast
• Source: Shutterstock

"My policy as a doctor was always to be very open and transparent – whether that was about morbidity or mortality I was very open.” 

In this latest instalment of the In Vivo podcast, Treehill Partners founder, CEO and chair Ali Pashazadeh focuses on the need for increased communication between biotech and pharma and their contract organizations (both research and development/manufacturing organizations). Pashazadeh also analyzes how his previous medical experience guides him now, as he attempts to transfer the same ethos held as a doctor and clinician to the world of investment banking.

Timestamps:

  • Introduction - 00:00
  • Clinal development optimization model - 2:37
  • Transferring between industries – 7:06
  • To what extent will AI impact research? - 11:56
  • China and the importance of early data - 15:23
  • Looking ahead - 16:35  

More from Deal-Making

In Conversation: Sketching The Future Of Biotech Investment With Lilly Ventures

 
• By Jo Shorthouse

Laura Lane, European head of Lilly Ventures, talked to In Vivo at the recent Bio-Europe meeting in a fireside chat about how strategic investments are shaping the future of biotech, Lilly's approach to early-stage innovation, and the evolving European investment landscape.

TechBio’s Next Wave: Where AI Meets Biology And Investment Opportunity

 
• By David Wild

TechBio stands at a critical inflection point, where computational innovation meets the reality of biopharma. Industry leaders have begun to cut through the hype and identify where sustainable value truly lies in this rapidly evolving landscape.

Deals In Depth: February 2025

 
• By Deanna Kamienski and Maureen Riordan

Three $1bn+ alliances were penned in February, and one exceeded $2bn.

Deals Shaping The Industry, February 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during February 2025. Data courtesy of Biomedtracker.

More from In Vivo

TechBio’s Next Wave: Where AI Meets Biology And Investment Opportunity

 
• By David Wild

TechBio stands at a critical inflection point, where computational innovation meets the reality of biopharma. Industry leaders have begun to cut through the hype and identify where sustainable value truly lies in this rapidly evolving landscape.

Deals In Depth: February 2025

 
• By Deanna Kamienski and Maureen Riordan

Three $1bn+ alliances were penned in February, and one exceeded $2bn.

Mirum’s Rare Disease Strategy: A Blueprint For Sustainable Growth

 
• By David Wild

From a $7m discarded asset to a $336m commercial portfolio, In Vivo looks inside Mirum Pharma’s disciplined strategy for identifying, acquiring and revitalizing overlooked rare disease programs while building toward billion-dollar potential.